Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...

"Additionally, thyroid dysfunction and environmental ... Research also has shown that exacerbations persistently worsen the myasthenia gravis disease course, even after appropriate therapy.

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with ...

Opens in a new tab or window Myasthenia gravis (MG) results from autoimmune ... Some patients with AChR disease do not respond well to complement inhibition, underscoring the relevance of other ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities ... Phase 3 studies of batoclimab in thyroid eye disease are available.

Sunshine Cruz shared that she has been diagnosed with an autoimmune disease, just a few days after walking in the Bench Body of Work fashion show. The 47-year-old actress revealed on social media that ...

Myasthenia gravis is a serious, rare, and chronic neuromuscular autoimmune disease that can cause debilitating and potentially life-threatening muscle weakness. There are around 60,000 to 120,000 ...

Myasthenia Gravis [MG] is characterized as an autoimmune ... generation anti-FcRn in the targeting of patients with Thyroid Eye Disease or TED. This leads to the next program I'm going to go ...

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...